Graft Versus Host Disease (GVHD) Market – By Disease Type (aGVDH, cGVDH), Treatment Type (Monoclonal Antibodies, mTOR Inhibitors, Immunosuppressants, Corticosteroids), Age Group, Route of Administration, Distribution Channel – Global Forecast 2024 – 2032

Graft Versus Host Disease Market Size

Graft Versus Host Disease Market size was valued at USD 2.5 billion in 2023 and is expected to reach USD 5.1 billion by 2032 growing at a CAGR of 8.1% over the analysis period, due to the increasing prevalence of hematological disorders and malignancies necessitating hematopoietic stem cell transplantation (HSCT).
 

The global increase in HSCT procedures has correspondingly driven up the incidence of GVHD, necessitating the need for effective therapeutic solutions to address this complication. Despite considerable advancements in donor selection, conditioning regimens, and supportive care, GVHD remains prevalent, thereby impacting approximately 30% to 50% of patients undergoing allogeneic HCT. A study published in (NCBI) stated that 42% of U.S. patients developed cGVHD within three years post-allogenic HSCT, often preceded by acute GVHD. This surge in the patient population affected by GVHD fuelled the development and adoption of novel treatments, thereby contributing to market expansion.
 

GVHD arises following hematopoietic stem cell or bone marrow transplantation, characterized by the donor's immune cells (graft) attacking the recipient's tissues (host). The immune reaction triggers inflammation and organ damage, affecting vital areas such as the skin, liver, gastrointestinal tract, and lungs. Also, the GVHD poses a substantial hurdle in transplantation, influencing patient well-being and necessitating specialized therapies to address its manifestations and complexities.
 

Graft Versus Host Disease Market Trends

• The surge in market growth is driven by escalating rates of bone marrow or hematopoietic stem cell treatments, coupled with a growing incidence of GVHD, prompting the development of innovative therapies. To address the global demand for novel treatments, pharmaceutical companies heavily investing to intensify research endeavors, expanding their product portfolios.
   
• For instance, in December 2021, the U.S. (FDA) approved Orencia for preventing aGVHD when used alongside specific immunosuppressants. This approval is extended to adult and pediatric patients aged two years and older undergoing HCT from an unrelated donor. The approval aimed to drive market growth by introducing effective treatment options to address the global demand for rare disease management.
   
• Similarly, Equillium Inc.'s completion of an End-of-Phase 1 meeting with the US FDA for itolizumab in aGvHD treatment presents promising prospects. Positive clinical trial outcomes are expected to introduce new treatments.
   

Graft Versus Host Disease Market Analysis

Based on disease type, the market is classified into acute graft versus host disease (aGVDH) and chronic graft versus host disease (cGVDH). The aGVDH segment has asserted its dominance in the global market by securing a significant share and experiencing growth of 7.9% between 2024 - 2032.
 

• Factors such as higher incidence rates of acute GVHD, greater emphasis on R&D for treatments, or the effectiveness of existing therapies targeting aGVHD manifestations is expected to spur the segmental growth. For instance, according to a StatPearls Publishing report in October 2021, acute GVHD incidence reached approximately 50% in patients receiving HCT.

Based on the treatment type, the GVHD market is categorized into monoclonal antibodies, mTOR Inhibitors, tyrosine kinase inhibitors, immunosuppressants, corticosteroids, and other treatment types. The immunosuppressants segment held the largest market share of 33.9% in 2023.
 

• Immunosuppressants are paramount in managing GVHD by suppressing the donor's immune response against the recipient's tissues post-transplantation. Therefore, their widespread adoption and efficacy in controlling GVHD manifestations underscore their dominance within the market, reflecting their indispensable status in the standard of care for GVHD treatment across various clinical settings.
   

Based on age group, the graft versus host disease market is classified into 20 years, 21-50 years, and 51 years and above. The 51 years and above segment accounted for USD 1.2 billion in 2023.
 

• The high market share is attributable to factors such as increased incidence of hematologic malignancies or autoimmune disorders requiring stem cell transplantation in older individuals.
   
• Additionally, age-related changes in immune function may contribute to heightened GVHD risk. Recognizing this demographic helps in tailoring treatment strategies and allocating resources effectively to address the specific needs of older patients afflicted with GVHD.
   

Based on the route of administration, the graft versus host disease market is classified into oral, intravenous, and topical. The intravenous segment is expected to reach USD 2.8 billion by 2032.
 

• The widespread utilization and efficacy in delivering therapeutic interventions for GVHD management have strengthened the preference for intravenous routes.
   
• Also, intravenous administration offers direct access to the bloodstream, facilitating the systemic distribution of medications, which is crucial for treating multisystem manifestations of GVHD effectively.
   

Based on the distribution channel, the graft versus host disease market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies segment is expected to reach USD 2.4 billion by 2032.
 

• Hospital pharmacies lead the GVHD market due to their pivotal role in providing immediate access to specialized medications and therapies required for GVHD management within healthcare institutions. Their integration within hospital settings ensures streamlined coordination with healthcare professionals, facilitating prompt administration of treatments to patients undergoing transplantation.
   
• Additionally, hospital pharmacies offer comprehensive pharmaceutical care, including dosage adjustments, medication counseling, and discounts, contributing to improved patient outcomes and reinforcing their dominance in the market.

North America is projected to maintain its lead in the global graft versus host disease market, anticipated to reach USD 2.1 billion by 2032.
 

• North America's dominance in the market is attributed to its robust healthcare infrastructure, growing R&D activities, and escalating transplant rates. According to Organ Procurement and Transplantation Network data, U.S. witnessed more than 20,500 transplant procedures between January 2022 and June 2022. This surge in transplants anticipated the demand for GVDH treatments, fueled by immune-mediated responses between donors and recipients, thereby driving the market expansion.
   

Graft Versus Host Disease Market Share

The GVHD industry exhibited high competitiveness with several players vying for prominence. Key competitors are utilizing diverse GVHD treatment portfolios to sustain market dominance, while others are providing specialized therapies. Competition pivoted on factors such as product efficacy, safety, regulatory approvals, and pricing, advancing innovation and collaborative efforts among industry stakeholders to drive advancements in the field.
 

Graft Versus Host Disease Market Companies

Prominent players operating in the graft versus host disease industry are as mentioned below:

• Astellas Pharma Inc.
• Bristol Myers Squibb
• ElsaLys Biotech SA
• Incyte Corporation
• Johnson & Johnson Services, Inc.
• Kiadis Pharma
• Mallinckrodt Pharmaceuticals
• Merck & Co., Inc.
• Mesoblast Ltd.
• Neovii Pharmaceuticals AG
• Novartis AG
• Pfizer Inc.
• Sanofi
• Soligenix
   

Graft Versus Host Disease (GVHD) Industry News:

• In February 2024, Incyte has been granted Priority Review by the U.S. FDA for axatilimab, an anti-CSF-1R antibody, for chronic GVHD treatment. This follows positive outcomes from the AGAVE-201 trial, presenting a market opportunity for an effective GVHD treatment.
   
• In May 2022, Novartis received the European Commission approval for Jakavi for patients aged 12 and above with acute or chronic GvHD, unresponsive to corticosteroids or other systemic therapies. This expanded indication aimed at redefining GVDH treatment for non-responsive patients, thereby providing new therapeutic options.
   

The graft versus host disease market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Acute graft versus host disease (aGVHD)
• Chronic graft versus host disease (cGVHD)

Market, By Treatment Type

• Monoclonal antibodies
• mTOR inhibitors
• Tyrosine kinase inhibitors
• Immunosuppressants
• Corticosteroids
• Other treatment types

Market, By Age Group

• 20 years
• 21-50 years
• 51 years and above

Market, By Route of Administration

• Oral
• Intravenous
• Topical

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa